University of California

Los Angeles Biomedical Research Institute at Harbor-Ucla Medical Center

Harbor-Ucla Research and Education Institute

Joseph A Zasadzinski

Alan J Waring

Frans J Walther

Larry M Gordon

Scott A Walker

Michael T Kennedy

Bret A Coldren

Edward T Kisak

A composition including a C terminal region having residues corresponding to a peptide identified by PDB ID: 1RG3; an N terminal region having residues corresponding to a peptide identified by PDB ID: 1RG4; and a disulfide linkage between the residues near the C terminal region and the N terminal region. A composition including an exogenous peptide comprising amino acid residues comprising a C terminal region; amino acid residues comprising an N terminal region; a helix-loop-helix conformation between the residues comprising the C terminal region and the residues including the N terminal region; and at least one disulfide linkage between the residues comprising the C terminal region and the residues including N terminal region, wherein the residues including the C terminal region and the residues comprising the N terminal region have an amphiphatic property, and wherein the peptide has an a biological activity comparable to native surfactant protein SP-B. A method including delivering to a body a composition comprising an exogenous peptide having a biological activity comparable to native surfactant protein SP-B. A kit including an exogenous peptide having a biological activity comparable to native surfactant protein SP-B; and a treatment agent different from the peptide.

Exogenous surfactant protein B mimic

A therapeutic pharmaceutical composition for the treatment of respiratory disease is disclosed, including particularly Respiratory Distress Syndrome (RDS). The composition is comprised of a synthetic dimer of an N-terminal fragment of Surfactant Protein B (SP-B) that advantageously mimics the functional activity of native human Surfactant Protein B, and to therapeutic methods of administration of such pharmaceutical compositions.

Respiratory distress syndrome therapy with peptide analogs of human SP-B

The present invention provides compositions and methods of preparing a bilayer structure for encapsulating multiple containment units. These containment units can contain therapeutic, diagnostic agents or imaging agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.

Bilayer structure which encapsulates multiple containment units and uses thereof

The present invention provides a bilayer structure for encapsulating multiple containment units. These containment units can attach or contain therapeutic or diagnostic agents that can be released through the bilayer structure. A suitable example of such a containment unit is a unilamellar or multilamellar vesicle.

Growing community of inventors

Santa Barbara, CA, United States of America

Joseph A Zasadzinski